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Abstract 
Background: In order to decrease the incidence of ventilator-associated pneumonia (VAP) in Belgium, a national 
campaign for implementing a VAP bundle involving assessment of sedation, cuff pressure control, oral care with 
chlorhexidine and semirecumbent position, was launched in 2011–2012. This report will document the impact of this 
campaign.
Methods: On 1 day, once a year from 2010 till 2016, except in 2012, Belgian ICUs were questioned about their ven-
tilated patients. For each of these, data about the application of the bundle and the possible treatment for VAP were 
recorded.
Results: Between 36.6 and 54.8% of the 120 Belgian ICUs participated in the successive surveys. While the character-
istics of ventilated patients remained similar throughout the years, the percentage of ventilated patients and espe-
cially the duration of ventilation significantly decreased before and after the national VAP bundle campaign. Ventilator 
care also profoundly changed: Controlling cuff pressure, head positioning above 30° were obtained in more than 90% 
of cases. Oral care was more frequently performed within a day, using more concentrated solutions of chlorhexidine. 
Subglottic suctioning also was used but in only 24.7% of the cases in the last years. Regarding the prevalence of VAP, it 
significantly decreased from 28% of ventilated patients in 2010 to 10.1% in 2016 (p ≤ 0.0001).
Conclusion: Although a causal relationship cannot be inferred from these data, the successive surveys revealed a 
potential impact of the VAP bundle campaign on both the respiratory care of ventilated patients and the prevalence 
of VAP in Belgian ICUs encouraging them to follow the guidelines.
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Background
Ventilator-associated pneumonia (VAP) is among the 
most common type of intensive care unit (ICU)-acquired 
infection and is associated with significant morbid-
ity and mortality [1]. In Europe, the incidence remains 
higher than in the USA despite the implementation of 
VAP bundles [2–4]. The need for the implementation of 
multimodal approach to decrease the incidence of VAP 
has been recently reemphasized by European guidelines 
[5] and especially by guidelines coming from the société 
française d’anesthésie-réanimation and the société de 
réanimation de langue française [6, 7]. Besides the use 
of selective digestive decontamination, these guidelines 
support the use of 6 procedures: avoiding intubation 
by the use of noninvasive ventilation, avoiding nasotra-
cheal intubation, controlling cuff pressure, reducing the 
level of sedation, early enteral nutrition and subglottic 
suctioning.
In Belgium, after having observed high rate of VAP in 
ICUs from previous surveys, the federal service launched 
a promotional campaign to implement a national VAP 
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bundle in 2011. This campaign involved several meetings 
in Brussels (attended by representatives from most Bel-
gian ICUs) where the Belgian VAP bundle was explained 
and promoted. This campaign was followed by a prospec-
tive collect of all the VAP bundle data during 11 months 
in 2012 from voluntary participating Belgian ICUs. 
This collect was performed by the federal service. The 
national VAP bundle involved 4 items: a protocol with 
daily assessment of sedation, a semirecumbent position 
of at least 30°, the control of cuff pressure between 20 
and 30 cm of H2O and the oral care with chlorhexidine. 
In addition, the use of subglottic suctioning was encour-
aged. Before and after this campaign, the college of physi-
cians for intensive care, which also relies on the federal 
public service for health, food chain safety and environ-
ment, has performed surveys to evaluate the prevalence 
of VAP in Belgian ICUs. The present paper describes the 
results of the successive surveys and will examine the 
impact the campaign could have on the compliance of 
medical teams for implementing the bundle and on the 
prevalence of VAP. Data from the 2012 national collec-
tion study have been already published [8].
Methods
Once a year, from 2010 till 2016, except in 2012, all the 
120 adult ICUs in Belgium received an invitation to par-
ticipate in 1-day survey performed by the college of physi-
cians for intensive care about ventilated patients and the 
occurrence of VAP. ICUs were asked about their num-
ber of beds, their occupancy, the number of ventilated 
patients. Ventilated patient characteristics included age, 
sex, primary reason for ICU admission, comorbidities, 
date of admission to the hospital and to the ICU, date of 
intubation and cause of ventilation. Regarding ventilation 
care, the way of intubation (nasal, oral, tracheostomy),the 
type of cuff (polyvinyl, polyurethane), the current cuff 
pressure, the type of suctioning system (opened or 
closed), the current head positioning, the moistening sys-
tem (heat and moisture exchangers, active devices) and 
the use of a subglottic suctioning system were recorded 
for each patient. Regarding the oral care, the type of disin-
fection (chlorhexidine, polyvidone iodine, other), the rate 
of disinfection, the use of dental brushing and the type 
of nutrition tubing (nasogastric, orogastric, postpyloric 
tube, gastrostomy or jejunostomy) were also recorded for 
each ventilated patients. If a patient was treated for a VAP, 
the bacteriological results were asked for and the sever-
ity of the infection according to the grade of sepsis was 
recorded. No follow-up of patients was obtained.
VAP diagnosis was based on new infiltrate on chest 
X-ray with either fever above 38° or less than 35° or leu-
kocytosis above 10,000 white blood cells/mm3 and either 
occurrence of purulent tracheal secretions or decrease in 
PaO2/FiO2. After each survey, all the ICUs, having or not 
participated in the survey, received a report describing 
the results and were encouraged to continue to imple-
ment the VAP bundle.
Statistical analysis
Quantitative data were summarized as median and inter-
quartile (IQR) values or as mean and SD when normally 
distributed. Comparisons were made by the Kruskal–
Wallis or Student’s t test as appropriate for continuous 
variables and by Chi-square or Fisher’s exact test for cat-
egorical variables. All tests were two-sided, and statistical 
significance was set at p less than 0.05.
Results
More than 60 adult ICUs participated in the surveys, 
except in 2016 when there were only 44. Considering that 
in Belgium there are 120 acute hospitals, these figures 
correspond to 36.6–54.8% of them. Figure  1 gives the 
evolution of the number of ICU beds belonging to par-
ticipating ICUs, the number of patients and among them, 
the number of ventilated patients. As can be inferred 
from Fig.  1, the percentage of bed occupancy remained 
stable, between 75 and 80%, but the percentage of venti-
lated patients decreased significantly from 44.8% in 2010 
to 28.7% in 2016 (p < 0.05). Another impressive differ-
ence between the surveys was the decrease in the dura-
tion of ventilation from the ICU admission till the day 
of the survey: The median was 10.5 and 13  days before 
the campaign, then 7, 5, 5 and 6 days after the campaign 
(p < 0.001) (Table 1).
The other characteristics of ventilated patients 
remained quite the same throughout the years of the sur-
veys as shown in Table 1: age, sex, pre-ICU hospitaliza-
tion stays, types of patients, underlying diseases, none of 
these characteristics differ between years of survey. How-
ever, regarding the causes of ventilation, the differences 
reached the statistical significance (p = 0.0012).
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Fig. 1 Evolution of the number of ICU beds, patients and ventilated 
patients in participating ICUs
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Regarding ventilatory care, it profoundly changed 
before and after the national VAP bundle campaign: As 
shown in Table 2, the cuff pressure measurement, which 
was not performed in 27% of ventilated patients in 2011, 
was obtained in more than 90% of cases in 2015. Head 
positioning above 30° was seen in 2010 only in 54% of 
ventilated patients, and it was systematically observed 
in more than 90% of the patients after the campaign 
except in 2016, when it decreased to 88.6%. Subglottic 
suctioning also significantly increased, and it was how-
ever used in only 24.7% of the cases in 2016. In the same 
way, oral care was more frequently performed, using 
more concentrated solutions of chlorhexidine as shown 
in Table 3. Other oral disinfectants were less often used 
(from 15.2% in 2010 to 6.3% in 2016), polyvidone iodine 
solutions remaining at a level of 34.8% in 2016. Dental 
brushing which was not performed in 25% of the venti-
lated patients in 2011 was still not done in 17.1% of the 
patients in 2016.
Regarding the prevalence of VAP, it significantly 
decreased from 28% of ventilated patients in 2010 to 
10.1% in 2016 as shown in Fig. 2 (p   ≤ 0.0001). Interest-
ingly, the associated bacteremia also decreased in abso-
lute terms (from 7 to 2) but not relatively (from 8.9 to 
12.5% of the corresponding VAP, p = 0.9625).
Discussion
This paper reports on the implementation of a VAP bun-
dle in Belgium. It was indeed expected in 2012 by the 
federal authorities to at least halve the VAP incidence 
Table 1 Characteristics of ventilated patients
IQR Interquartile range, ICU intensive care unit, COPD chronic obstruction pulmonary disease, NA not available
Characteristics of patients
2010 2011 2013 2014 2015 2016 p value
Number 129 293 288 265 271 158
Age median (IQR) 67 (54–78) 65 (54–75) 66 (54–75) 67 (57–76) 64 (54–76) 64 (50–71) 0.8412
Sex (male) 88 (68.8%) 183 (62.5%) 183 (63.5%) 162 (61.1%) 170 (62.7%) 102 (64.6%) 0.8326
Pre-ICU hosp. stay 0 (0–4) 0 (0–2) 0 (0–2) 1 (0–5) 0 (0–2) 0 (0–2) 0.3229
ICU stay median 10 (4–19) 13 (7–21) 8 (3–18) 7 (2–16) 7 (2–16) 8 (2–19) < 0.0001
Duration of ventilation median 10.5 (4–17) 13 (7–21) 7 (3–16) 5 (2–14) 5 (1–15) 6 (2–14) < 0.0001
Type of patients 0.0655
Medical 71 (55.8%) 156 (53.2%) 155 (53.2%) 138 (52.1%) 153 (56.5%) 94 (59.4%)
Scheduled surgery 12 (9.3%) 51 (17.4%) 57 (19.8%) 52 (19.6%) 45 (16.6%) 18 (11.4%)
Nonscheduled surgery 32 (24.8%) 51 (17.4%) 48 (16.7%) 59 (22.3%) 42 (15.5%) 30 (19%)
Trauma 13 (10.1%) 35 (16.1%) 28 (9.7%) 16 (6%) 31 (11.4%) 16 (10.1%)
Underlying disease 0.2724
Smoker 44 (34.1%) 102 (47%) 103 (35.7% 75 (28.3%) 81 (29.9%) 51 (32.3%)
Asthma 7 (5.4%) 13 (4.4%) 5 (1.7%) 19 (7.2%) 9(3.3%) 5 (3.2%)
COPD 36 (27.9%) 83 (28.3%) 89 (30.9%) 63 (23.8%) 64 (23.6%) 38 (24%)
Solid cancer 4 (3.1%) 36 (12.3%) 28 (9.7%) 28 (10.6%) 20 (7.4%) 12 (7.6%)
Hematological cancer 7 (5.4%) 7 (2.4%) 10 (3.5%) 4 (1.5%) 9 (3.3%) 4 (2.5%)
Immunosuppression 12 (9.3%) 25 (8.5%) 20 (6.9%) 19 (7.2%) 16 (5.9%) 6 (3.8%)
Corticotherapy 9 (7%) 37 (12.6%) 28 (9.7%) 39 (14.7%) 27 (10%) 15 (9.5%)
Diabetes 13 (10.1%) 38 (13%) 42 (14.6%) 34 (12.8%) 34 (12.5%) 17 (10.8%)
Other NA NA NA 26 (9.8%) 26 (9.6%) 75 (47.4%)
Cause of ventilation 0.0012
Hypoxia 50 (38.8%) 79 (27%) 95 (33%) 83 (31.3%) 80 (29.5%) 55 (34.8%)
Hypercapnia 7 (5.4%) 39 (13.3%) 24 (8.3%) 19 (7.2%) 11 (4.1%) 16 (10.1%)
Central nervous system 24 (18.6%) 47 (16%) 40 (13.9%) 32 (12.1%) 45 (16.6%) 19 (12%)
Peripheral nervous system 0 (0%) 1 (0.3%) 2 (0.7%) 4 (1.5%) 5 (1.8%) 2 (1.3%)
Trauma 7 (5.4%) 14 (4.8%) 12 (4.2%) 9 (3.4%) 14 (5.2%) 10 (6.3%)
Circulatory problem 17 (13.2%) 38 (13%) 40 (17.4%) 40 (15.1%) 43 (15.9%) 17 (10.8%)
Postoperative 17 (13.2%) 30 (10.2%) 59 (20.5%) 67 (25.2%) 63 (23.2%) 25 (15.8%)
Other 7 (5.4%) 13 (1.1%) 16 (5.6%) 11 (4.1%) 10 (3.7%) 14 (8.9%)
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Table 2 Ventilatory care
NIV Noninvasive ventilation
2010 2011 2013 2014 2015 2016 p value
Previous NIV 25 (19.4%) 50 (17.1%) 52 (18%) 46 (17.4%) 44 (16.2%) 33 (20.9%) 0.8685
Artificial airway 0.0663
Oral intubation 95 (75.4%) 244 (83.3%) 234 (81.2%) 222 (83.8%) 226 (83.4%) 132 (83.5%)
Nasal intubation 0 2 (0.7%) 4 (1.4%) 4 (1.6%) 6 (2.2%) 2 (1.3%)
Tracheostomy 34 (26.4%) 47 (16%) 50 (17.4%) 39 (14.7%) 39 (14.4%) 24 (15.2%)
Cuff 0.0318
Polyvinyl 74 (64.3%) 166 (56.6%) 170 (59%) 143 (54%) 158 (58.3%) 110 (69.6%)
Polyurethane 41 (36.7%) 127 (43.3%) 118 (41%) 122 (46%) 113 (41.7%) 48 (30.4%)
Cuff pressure < 0.0001
Not measured 9 (7%) 72 (24.6%) 2 (0.7%) 10 (3.8%) 4 (1.5%) 6 (3.8%)
< 20 cm  H2O 25 (19.4%) 18 (6.1%) 9 (3.1%) 9 (3.4%) 2 (0.7%) 7 (4.4%)
20–30 cm  H2O 91 (70.5%) 196 (66.9%) 263 (91%) 228 (86%) 251 (92.6%) 137 (86.7%)
> 30 cm  H2O 4 (3.1%) 6 (2%) 10 (3.5%) 15 (5.7%) 10 (3.7%) 5 (3.2%)
Not inflated 0 1 (0.3%) 4 (1.4%) 3 (1.1%) (1.5%) 3 (1.9%)
Suctioning system < 0.0001
Opened 76 (62.8%) 236 (80.5%) 204 (70.8%) 171 (64.5%) 205 (75.6%) 120 (79.7%)
Closed 45 (37.2%) 57 (19.5%) 84 (29.2%) 94 (35.5%) 66 (24.4%) 38 (20.3%)
Subglottic suctioning < 0.0001
Yes 7 (5.8%) 67 (22.9%) 94 (32.6%) 60 (22.6%) 70 (25.8%) 39 (24.7%)
No 114 (94.2%) 226 (77.1%) 194 (69.2%) 205 (77.4%) 201 (74.2%) 119 (75.3%)
Head position < 0.0001
< 30° 55 (44.4%) 43 (14.7%) 21 (7.3%) 13 (4.9%) 25 (9.2%) 18 (11.4%)
> 30° 67 (54.0%) 249 (85%) 262 (91%) 249 (94%) 245 (90.4%) 140 (88.6%)
Prone position 2 (1.6%) 1 (0.3%) 5 (1.7%) 3 (1.1%) 1 (3.7%) 0 (0%)
Table 3 Oral care
CHXD Chlorhexidine, NK: not known
Oral disinfection 2010 2011 2013 2014 2015 2016 p value
Water 1 (1%) 6 (2%) 1 (0.3%) 0 (0%) 0 (0%) 0 (0%)
CHXD 0.2% 48 (38.4%) 126 (43%) 108 (37.5%) 132 (49.8%) 90 (33.2%) 79 (50%) < 0.0001
CHXD 0.5% 13 (10.4%) 5 (1.7%) 11 (3.8%) 7 (2.6%) 4 (1.5%) 5 (3.2%)
CHXD 1% 0 (0%) 2 (0.7%) 26 (9%) 7 (2.6%) 16 (5.9%) 3 (1.9%)
CHXD 2% 0 (0%) 0 (0%) 10 (3.5%) 9 (3.4%) 15 (5.5%) 7 (4.4%)
Polyvidone iodine 44 (35.2%) 119 (40.6%) 102 (35.4%) 93 (35.1%) 124 (45.8%) 55 (34.8%)
Other 19 (15.2%) 35 (11.9%) 30 (10.4%) 17 (6.4%) 22 (8.11%) 10 (6.3%)
Rate of disinfection
1/day 2 (1.6%) 31 (10.6%) 3 (1%) 9 (3.4%) 2 (0.7%) 0 (0%) < 0.0001
2/day 24 (19.2%) 41 (14%) 24 (8.3%) 27 (10.2%) 22 (8.1%) 8 (5.1%)
3/day 36 (28.8%) 117 (39.9%) 158 (54.9%) 136 (51.3%) 116 (42.8%) 75 (47.4%)
> 3/day 63 (50.4%) 104 (35.5%) 103 (35.8%) 93 (35.1%) 131 (48.3%) 75 (47.4%)
Dental brushing
0/day NK 63 (21.5%) 51 (18.7%) 32 (12.9%) 36 (13.3%) 27 (17.1%) 0.0235
1/day NK 99 (33.8%) 103 (35.8%) 88 (33.3%) 83 (30.6%) 63 (39.9%)
2/day NK 70 (23.9%) 63 (21.9%) 81 (38.6%) 84 (31%) 51 (32.3%)
2/day NK 46 (15.7%) 47 (16.3%) 45 (17%) 53 (19.6%) 11 (7%)
Not applicable NK 15 (5.1%) 25 (8.7%) 19 (7.2%) 15 (5.5%) 6 (3.8%)
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encountered in Belgium. According to Fig. 2, this seems 
to have been reached and even exceeded, since the preva-
lence of VAP, as estimated by the surveys, was as high as 
28% of the ventilated patients in 2010, reached 11.3% in 
2014 and was maintained at this level for the next 2 years. 
It does not correspond to prevalence levels reported in 
the USA, but it corresponds to the best levels reported in 
European centers where VAP bundles are implemented 
[3, 4].
There is no clear consensus about what a VAP bun-
dle should be [9, 10]. The first VAP bundle from the IHI 
includes elements which were not directly linked to the 
management of the airway (prevention of both throm-
boembolism and digestive hemorrhage) [11]. European 
experts proposed in 2010 only two procedures in addi-
tion to general measures such as hand hygiene, staff 
education and nonventilatory circuit change: control 
of sedation with protocol of weaning and oral care with 
chlorhexidine [12]. The Belgian VAP bundle [8] includes 
these two procedures into 4 components (sedation pro-
tocol, control of cuff pressure, oral disinfection, head of 
bed elevation) which were also parts of bundles recently 
published with reported efficacy [3, 4]. It also promotes 
a fifth procedure: subglottic suctioning which seems to 
have become the most useful procedure for the preven-
tion of VAP [13–15].
The most striking difference between surveys appeared 
to be the percentage of ventilated patients and the dura-
tion of ventilation from the ICU admission till the day of 
the survey. Although this latter parameter was not the 
true duration of ventilation, it reflects a reality which 
means that from year to year, at one point in the year, 
fewer patients were ventilated and especially for less time 
in Belgian ICUs. Of course, this reduction of duration of 
ventilation reduces the risk for occurrence of VAP, esti-
mated by these 1-day prevalence surveys. It would have 
been worth correlating this reduction of ventilation to 
a change in sedation procedures, which, unfortunately, 
were not directly assessed by the surveys. It may however 
be inferred that the campaign had an impact because of 
the clear difference between the duration before and after 
it.
After the campaign, the compliance with head of bed 
elevation and control of cuff pressure increased sig-
nificantly and exceeded 90%. Oral disinfection also 
improved. The type of antiseptic varied largely, but the 
rate of application increased: It was done at least 3 times 
a day in 79.2% in 2010 and in 94.8% in 2016 (p < 0.0001). 
Chlorhexidine concentration of 1 or 2% was more often 
used after the campaign, but the low concentration of 
0.2% was still used in 50% in 2016. The type and the con-
centration of antiseptic remain a matter of debate. Chlo-
rhexidine has been shown as effective with concentration 
as high as 2% in a well-conducted multicenter study in 
the Netherlands by Koeman in 2006 [16]. Chlorhexidine 
has been, however, reported to be sometimes not well 
tolerated by the patients [17]. More worrying is that an 
increase in mortality in patients receiving chlorhexidine 
as part of oral disinfection was recently reported by 
Komplas [18] although this agent is used worldwide [19]. 
The merit of polyvidone iodine in oral disinfection is sup-
ported by very few studies [19], although it remains used 
in Belgium in one-third of the patients. Regarding dental 
brushing, it is surprising that as many as 17.1% of patients 
did not benefit from this care in 2016. They were already 
21.5% in 2010, though dental brushing is the only way to 
eliminate or reduce the dental plaque which can contain 
a lot of pathogenic bacteria [20]. However, even if dental 
brushing has been shown to reduce the rate of pneumo-
nia in postoperative patients [21], this was curiously not 
yet confirmed for VAP in ventilated ICU patients [22]. 
Subglottic suctioning, which was promoted, remains 
used in Belgium in a minority of patients. This could 
be due to the cost of the endotracheal tube which is on 
average 10 times higher than conventional tubes in Bel-
gium. However, this procedure should still be encouraged 
because of its efficacy reported as high as 50% reduction 
of VAP incidence [15].
Thus, the VAP bundle was rather correctly followed 
and VAP incidence decreased. Was there a clear causal 
relationship between these two facts? These surveys can-
not ascertain that statement, but they were carried out 
to control the expected impact on VAP prevalence. But 
the question remains of the reality of this impact, espe-
cially because the effect was seen only in 2014, 2015 and 
2016, while the campaign was conducted in 2012. All the 
improvements seen in the application of VAP bundle 
were, however, already obtained in 2013. Why did the 
reduction in VAP prevalence not occur in 2013? In fact, 
this question is not anecdotic, because there may have 
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Fig. 2 Percentage of ventilated patients treated for VAP the day of 
the survey
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been a change in the way the VAP was diagnosed and 
the reduction seen in 2013 onward could be due to this 
change. As said by Komplas, “an apparent decrease in 
VAP rate could be achieved by maximally exploiting the 
subjectivity and inconstancies of VAP definitions” [23]. 
In our opinion, it was not the case, because the way of 
diagnosing VAP remains the same, based on radiological 
findings, the occurrence of fever, change in leukocytosis 
and bacteriological results. The surveys were answered 
on a voluntary basis, and there were no reasons to mini-
mize the VAP prevalence at any time. Most medical 
teams were the same during the surveys. An indirect evi-
dence of the reality in the reduction of VAP prevalence 
was the corresponding decrease in associated bactere-
mia, the rate relating to the number of VAP being stable. 
That means that the same type of infections was taken 
into account during the surveys. However, Komplas’ 
concern regarding the data manipulation, even if uncon-
scious, may still be real.
This report is not a true study such as the one recently 
published about the Spanish experience [24]. It is only 
a presentation of several surveys supporting the imple-
mentation of a VAP bundle in ICU ventilated patients. 
It gives figures from a large number of ICUs, allowing to 
describe the average activity of intensive care in Belgium 
and to encourage Belgian teams to prevent the occur-
rence of VAP by all valuable means. It is indeed interest-
ing to observe the steady decline in number of ventilated 
patients in Belgian ICUs and duration of ventilation over 
time. Data quality may be, however, questioned because 
data could not be controlled, but remained consistent 
over time.
Conclusion
The occurrence of VAP was a real issue in 2010 in Bel-
gium. The efforts made by the medical and nurses teams 
of the different ICUs seem to have successfully contrib-
uted to the decrease in VAP prevalence which has now 
reached a low plateau for several years. However, there 
could still be room for further improvement.
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